All In Biotech

Drug Trial Radar · NCT05551104

Safest Choice of Antihypertensive Regimen for Postpartum Hypertension

Safest Choice of Antihypertensive Regimen for Postpartum Hypertension: A Randomized Control Trial (SCARPH)

Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

May 8, 2023

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Loma Linda UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.

Conditions

  • Postpartum Complication
  • Maternal Hypertension
  • High Blood Pressure

Interventions

  • Oral NifedipineDrug

    Administration of oral nifedipine to control postpartum hypertension.

  • Oral LabetalolDrug

    Administration of oral labetalol to control postpartum hypertension.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite maternal morbidityTime frame: 0-6 weeks following delivery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Loma Linda University Health

    Loma Linda, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.